BRIAN JAY DRUKER, MD
Osteopathic Medicine at Sam Jackson Park Rd, Portland, OR
License number
Oregon MD18379
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
3181 SW Sam Jackson Park Rd, Portland, OR 97239
Phone
(503) 494-5596
(503) 494-3688 (Fax)
(503) 494-3688 (Fax)
Personal information
See more information about BRIAN JAY DRUKER at radaris.comName
Address
Phone
4100 SW Dosch Rd, Portland, OR 97239
235 Hooker St, Portland, OR 97201
23 Hooker St, Portland, OR 97201
3181 Sam Jackson Park Rd, Portland, OR 97201
Professional information
Dr. Brian J Druker, Portland OR - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
Oregon Health Sciences University HO
3181 SW Sam Jackson Park Rd SUITE L58, Portland 97239
(503) 494-8534 (Phone)
3181 SW Sam Jackson Park Rd SUITE L58, Portland 97239
(503) 494-8534 (Phone)
Certifications:
Internal Medicine, 1984, Medical Oncology, 1987
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University Of California, San Diego, School Of Medicine
Graduated: 1981
Barnes Jewish Hospital S Campus
Dana Farber Cancer Institute
University Of California, San Diego, School Of Medicine
Graduated: 1981
Barnes Jewish Hospital S Campus
Dana Farber Cancer Institute
Selection Of Personalized Cancer Therapy Regimens Using Interfering Rna Functional Screening
US Patent:
2009031, Dec 17, 2009
Filed:
Nov 14, 2008
Appl. No.:
12/271629
Inventors:
JEFFREY W. TYNER - PORTLAND OR, US
BRIAN J. DRUKER - PORTLAND OR, US
MARC LORIAUX - PORTLAND OR, US
MARY V. LUTTROPP - GRESHAM OR, US
BRIAN J. DRUKER - PORTLAND OR, US
MARC LORIAUX - PORTLAND OR, US
MARY V. LUTTROPP - GRESHAM OR, US
International Classification:
C40B 30/06
US Classification:
506 10
Abstract:
Methods for screening cells obtained from a subject for aberrant kinase activity are disclosed. The methods include placing cells isolated from the subject in contact with a set of siRNAs, wherein each individual siRNA is at an addressable location on the array and specifically inhibits expression of a tyrosine kinase. The siRNA is introduced into the blood cells or bone marrow cells by electroporation. After introduction of the siRNA, the cells are then assayed for proliferation and/or viability as compared to a control. A decreased proliferation and/or viability of the cells as compared to a control identifies a siRNA that inhibits the proliferation and/or viability of the cells, thus identifying the tyrosine kinase having aberrant tyrosine kinase activity in the subject.
Mutant Jak3 Kinase In Human Leukemia
US Patent:
2009028, Nov 19, 2009
Filed:
Jan 19, 2007
Appl. No.:
12/161512
Inventors:
Valerie Goss - Seabrook NH, US
Roberto Polakiewicz - Lexington MA, US
Brian Druker - Portland OR, US
Denise Walters - Rochester MN, US
Roberto Polakiewicz - Lexington MA, US
Brian Druker - Portland OR, US
Denise Walters - Rochester MN, US
Assignee:
CELL SIGNALING TECHNOLOGY, INC. - Danvers MA
International Classification:
A61K 39/395, C07H 21/04, C07K 14/00, C12N 15/63, C12N 5/10, C12N 9/12, C07K 16/00, C12Q 1/68, G01N 33/53, A61K 31/7088, A61P 35/02
US Classification:
4241301, 536 231, 536 232, 530350, 4353201, 435325, 435194, 5303891, 5303913, 435 6, 435 71, 514 44 A
Abstract:
In accordance with the invention, a novel activating mutation (alanine 572 to valine) in JAK3 kinase has been discovered in human acute myelogenous leukemia (AML). The mutant JAK3 kinase was confirmed to drive the proliferation and survival of acute megakaryoblastic leukemia (AML-M7). The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant JAK3 kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the mutant polypeptides. The disclosed identification of this new mutant protein and enables new methods for determining the presence of mutant JAK3 kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the mutant proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.
Translocation And Mutant Csf1R Kinase In Human Leukemia
US Patent:
2009019, Aug 6, 2009
Filed:
Jun 20, 2008
Appl. No.:
12/214616
Inventors:
Valerie Goss - Seabrook NH, US
Robert Polakiewicz - Lexington MA, US
Brian Druker - Portland OR, US
Denise Walters - Rochester MN, US
Robert Polakiewicz - Lexington MA, US
Brian Druker - Portland OR, US
Denise Walters - Rochester MN, US
International Classification:
C12Q 1/68, C12N 15/11, C12N 15/00, C12N 15/87, C12N 5/06, C12P 21/00, C12N 9/96, C07K 16/18, G01N 33/574, C12Q 1/48
US Classification:
435 6, 536 232, 4353201, 435455, 435325, 435 697, 435188, 5303913, 435 723, 435 15, 435375
Abstract:
In accordance with the invention, a novel gene translocation, (3p21, 5q33), in human myelogenous leukemia (AML) that results in a fusion protein combining part of RNA Binding Protein-6 (RBM6) with Macrophage Colony Stimulating Factor-1 Receptor (CSF1R) kinase has now been identified. The RBM6-CSF1R fusion protein and truncated CSF1R kinase itself, which both retain CSF1R tyrosine kinase activity, were confirmed to drive the proliferation and survival of acute megakaryoblastic leukemia (AML-M7). The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant CSF1R kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein and truncated kinase enables new methods for determining the presence of these mutant CSF1R kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.
Ror1 As A Gene Target In Acute Lymphoblastic Leukemia
US Patent:
2013013, May 23, 2013
Filed:
Nov 17, 2011
Appl. No.:
13/299245
Inventors:
Jeffrey W. Tyner - Portland OR, US
Brian J. Druker - Portland OR, US
Vincent Bicocca - Portland OR, US
Bill H. Chang - Portland OR, US
Brian J. Druker - Portland OR, US
Vincent Bicocca - Portland OR, US
Bill H. Chang - Portland OR, US
International Classification:
A61K 31/713, A61K 31/7105, C40B 30/04, G01N 33/573, C12Q 1/48, C12Q 1/68, A61K 31/506, A61P 35/02
US Classification:
514 44 A, 51425219, 514 44 R, 435 74, 435 15, 435 613, 506 9, 435 612, 435 611, 435 614
Abstract:
Disclosed are methods of selecting a subject suspected of having or having leukemia, such as lymphoblast leukemia (B-ALL), for treatment with an agent that inhibits ROR1-regulated signaling activity. In some examples, cells obtained from the subject are screened for over expression of ROR1. In other examples, the cells are contacted with an agent that inhibits ROR1 signaling activity and a ROR1-regulated signaling activity is detected. An alteration in the ROR1-regulated signaling activity as compared to a control identifies the subject as one that would benefit from treatment with an agent that inhibits ROR1 signaling activity. Also disclosed are methods for identifying an agent for treating a subject with a ROR1-dependent leukemia or with a predisposition for developing a ROR1-dependent leukemia, and methods for treating or inhibiting a ROR1-dependent leukemia, such as B-ALL in a subject.
Mutated Abl Kinase Domains
US Patent:
2005020, Sep 15, 2005
Filed:
Oct 4, 2002
Appl. No.:
10/491603
Inventors:
Christophe Barthe - Martignas Sur Jalles, FR
Susan Branford - South Australia, AU
Amie Corbin - Portland OR, US
Brian Druker - Portland OR, US
Justus Duyster - Munich, DE
Andreas Hochhaus - Mannheim, DE
Timothy Hughes - South Australia, AU
Sebastian Kreil - Mannheim, DE
Thibaut Leguay - Bordeaux, FR
Francois-Xavier Mahon - Bordeaux, DE
Gerald Marit - Bordeaux, DE
Martin Muller - Heidelberg, DE
Chriatian Peschel - Munich, DE
Claude Preudhomme - Houdain, FR
Catherine Roche Lestienne - Lille, FR
Zbigniew Rudzki - South Australia, AU
Susan Branford - South Australia, AU
Amie Corbin - Portland OR, US
Brian Druker - Portland OR, US
Justus Duyster - Munich, DE
Andreas Hochhaus - Mannheim, DE
Timothy Hughes - South Australia, AU
Sebastian Kreil - Mannheim, DE
Thibaut Leguay - Bordeaux, FR
Francois-Xavier Mahon - Bordeaux, DE
Gerald Marit - Bordeaux, DE
Martin Muller - Heidelberg, DE
Chriatian Peschel - Munich, DE
Claude Preudhomme - Houdain, FR
Catherine Roche Lestienne - Lille, FR
Zbigniew Rudzki - South Australia, AU
International Classification:
C12Q001/48, C07H021/04, C12N009/12, C12N015/09
US Classification:
435015000, 435194000, 435069100, 435320100, 435325000, 536023200
Abstract:
The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.
Detection Of Gleevec Resistance
US Patent:
7592142, Sep 22, 2009
Filed:
Jul 24, 2008
Appl. No.:
12/178926
Inventors:
Brian J. Druker - Portland OR, US
Amie Corbin - Portland OR, US
Amie Corbin - Portland OR, US
Assignee:
Oregon Health and Science University - Portland OR
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.
Detection Of Gleevec Resistance
US Patent:
2013027, Oct 17, 2013
Filed:
Jun 21, 2013
Appl. No.:
13/924369
Inventors:
Brian J. Druker - Portland OR, US
Amie Corbin - Portland OR, US
Amie Corbin - Portland OR, US
Assignee:
OREGON HEALTH & SCIENCE UNIVERSITY - Portland OR
International Classification:
C12Q 1/68
US Classification:
435 611
Abstract:
The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.
Treatment Of Gastrointestinal Stromal Tumors
US Patent:
2004002, Feb 5, 2004
Filed:
Aug 11, 2003
Appl. No.:
10/415015
Inventors:
Elisabeth Buchdunger - Neuenburg, DE
Renaud Capdeville - Riedesheim, FR
George Demetri - Brookline MA, US
Sasa Dimitrijevic - Habsheim, FR
Brian Druker - Portland OR, US
Jonathan Fletcher - Brookline MA, US
Michael Heinrich - Lake Oswego OR, US
Heikki Joensuu - Helsinki, FI
Sandra Silberman - Randolph NJ, US
David Tuveson - Berwyn PA, US
Renaud Capdeville - Riedesheim, FR
George Demetri - Brookline MA, US
Sasa Dimitrijevic - Habsheim, FR
Brian Druker - Portland OR, US
Jonathan Fletcher - Brookline MA, US
Michael Heinrich - Lake Oswego OR, US
Heikki Joensuu - Helsinki, FI
Sandra Silberman - Randolph NJ, US
David Tuveson - Berwyn PA, US
International Classification:
A61K031/506
US Classification:
514/252180
Abstract:
4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula (I) or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.
Organic Compounds
US Patent:
2003017, Sep 11, 2003
Filed:
Oct 3, 2002
Appl. No.:
10/263480
Inventors:
Christophe Barthe - Merignac, FR
Pascale Cony-Makhoul - Annecy, FR
Amie Corbin - Portland OR, US
Sven De Vos - Santa Monica CA, US
Brian Druker - Portland OR, US
Harald Gschaidmeier - Nurnberg, DE
Michael Hallek - Schondorf, DE
Andreas Hochhaus - Mannheim German, DE
Dieter Hoelzer - Frankfurt/Main, DE
Wolf-Karsten Hofmann - Goldbach, DE
Phillip Koeffler - Los Angeles CA, US
Sebastian Kreil - Mannheim, DE
Francois-Xavier Mahon - Bordeaux, FR
Martin Muller - Heidelberg, DE
Oliver Ottmann - Frankfurt/Main, DE
Markus Warmuth - Starnberg, DE
Pascale Cony-Makhoul - Annecy, FR
Amie Corbin - Portland OR, US
Sven De Vos - Santa Monica CA, US
Brian Druker - Portland OR, US
Harald Gschaidmeier - Nurnberg, DE
Michael Hallek - Schondorf, DE
Andreas Hochhaus - Mannheim German, DE
Dieter Hoelzer - Frankfurt/Main, DE
Wolf-Karsten Hofmann - Goldbach, DE
Phillip Koeffler - Los Angeles CA, US
Sebastian Kreil - Mannheim, DE
Francois-Xavier Mahon - Bordeaux, FR
Martin Muller - Heidelberg, DE
Oliver Ottmann - Frankfurt/Main, DE
Markus Warmuth - Starnberg, DE
International Classification:
G01N033/53, C07H021/04, C12N009/12, C12P021/02, C12N005/06
US Classification:
435/194000, 435/069100, 435/320100, 435/325000, 536/023200, 435/007100
Abstract:
The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.